Advanced Pharmacology – Midterm UPDATED ACTUAL Questions and
CORRECT Answers
1. Nurse practitioner prescriptive authority is regulated b. The State Board of
by: Nursing for each state
a. The National Council of Sate Board of Nursing
b. The State Board of Nursing for each state
c. The U. S. Drug Enforcement Administration
d. The State Board of Pharmacy
2. Eight Information needed for the prescription 1. Date of prescribing;
2. Name of patient(s);
3. Prescriber's name;
4. Name, strength, and
dosage of drug or device;
5. Number of refills, if ap-
plicable;
6. Quantity prescribed in
weight, volume, or num-
ber of units;
7. An indication of whether
generic substitution has
been authorized by the
prescriber;
8. Any change or alteration
made to the prescription
dispensed on contact with
the prescriber must show
a clear audit trail.
3. Three additional required information for controlled 1. Address of the pre-
substances scriber and patient;
2. The prescriber's DEA
number;
, 3 Controlled prescriptions
shall also comply with all
requirements of federal
and state controlled sub-
stance laws.
4. Who oversees the APRN's prescribing of controlled b. The federal government
substances? (DEA)
a. The pharmaceutical board of the state
b. The federal government (DEA)
c. The practice protocols of the hospital
d. Practice agreements
5. The USFDA regulates: b. The oflcial labeling
for all prescription and
a. Prescribing of drugs by medical doctors and nurse over-the-counter drugs
practitioners
b. The official labeling for all prescription and
over-the-counter drugs
c. Off-label recommendations for prescribing
d. Pharmaceutical educational offering
6. Medication agreements or "Pain Medication Con- a. Universally for all pre-
tracts" are recommended to be used: scribing for chronic pain
a. Universally for all prescribing for chronic pain
b. For patients who have repeated requests for pain
medication
c. When you suspect a patient is exhibiting drug-seek-
ing behavior
d. For patients with pain associated with malignancy
7.
, Anaphylactic shock is a: a. Type I reaction, called
immediate hypersensitivi-
a. Type I reaction, called immediate hypersensitivity ty reaction
reaction
b. Type II reaction, called cytotoxic hypersensitivity re-
action
c. Type III reaction, called immune complex hypersen-
sitivity
d. Type IV reaction, called delayed hypersensitivity re-
action
8. The role of the nurse practitioner with regards to c. Educate patients and
herbal medication is to: guide them to appropriate
sources of care.
a. Maintain competence in the prescribing of common
herbal remedies.
b. Recommend common over-the-counter herbs to pa-
tients.
c. Educate patients and guide them to appropriate
sources of care.
d. Encourage patients to not use herbal therapy due to
the documented dangers.
9. Prescribing for women during their childbearing years c. Possible unknown preg-
requires constant awareness of the possibility of: nancy
a. High risk for developmental disorders in their in-
fants
b. Decreased risk for abuse during this time
c. Possible unknown pregnancy
d. Possibility of drug allergies
10. c. NSAIDs
CORRECT Answers
1. Nurse practitioner prescriptive authority is regulated b. The State Board of
by: Nursing for each state
a. The National Council of Sate Board of Nursing
b. The State Board of Nursing for each state
c. The U. S. Drug Enforcement Administration
d. The State Board of Pharmacy
2. Eight Information needed for the prescription 1. Date of prescribing;
2. Name of patient(s);
3. Prescriber's name;
4. Name, strength, and
dosage of drug or device;
5. Number of refills, if ap-
plicable;
6. Quantity prescribed in
weight, volume, or num-
ber of units;
7. An indication of whether
generic substitution has
been authorized by the
prescriber;
8. Any change or alteration
made to the prescription
dispensed on contact with
the prescriber must show
a clear audit trail.
3. Three additional required information for controlled 1. Address of the pre-
substances scriber and patient;
2. The prescriber's DEA
number;
, 3 Controlled prescriptions
shall also comply with all
requirements of federal
and state controlled sub-
stance laws.
4. Who oversees the APRN's prescribing of controlled b. The federal government
substances? (DEA)
a. The pharmaceutical board of the state
b. The federal government (DEA)
c. The practice protocols of the hospital
d. Practice agreements
5. The USFDA regulates: b. The oflcial labeling
for all prescription and
a. Prescribing of drugs by medical doctors and nurse over-the-counter drugs
practitioners
b. The official labeling for all prescription and
over-the-counter drugs
c. Off-label recommendations for prescribing
d. Pharmaceutical educational offering
6. Medication agreements or "Pain Medication Con- a. Universally for all pre-
tracts" are recommended to be used: scribing for chronic pain
a. Universally for all prescribing for chronic pain
b. For patients who have repeated requests for pain
medication
c. When you suspect a patient is exhibiting drug-seek-
ing behavior
d. For patients with pain associated with malignancy
7.
, Anaphylactic shock is a: a. Type I reaction, called
immediate hypersensitivi-
a. Type I reaction, called immediate hypersensitivity ty reaction
reaction
b. Type II reaction, called cytotoxic hypersensitivity re-
action
c. Type III reaction, called immune complex hypersen-
sitivity
d. Type IV reaction, called delayed hypersensitivity re-
action
8. The role of the nurse practitioner with regards to c. Educate patients and
herbal medication is to: guide them to appropriate
sources of care.
a. Maintain competence in the prescribing of common
herbal remedies.
b. Recommend common over-the-counter herbs to pa-
tients.
c. Educate patients and guide them to appropriate
sources of care.
d. Encourage patients to not use herbal therapy due to
the documented dangers.
9. Prescribing for women during their childbearing years c. Possible unknown preg-
requires constant awareness of the possibility of: nancy
a. High risk for developmental disorders in their in-
fants
b. Decreased risk for abuse during this time
c. Possible unknown pregnancy
d. Possibility of drug allergies
10. c. NSAIDs
